- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Daiichi Sankyo Co Ltd ADR (DSNKY)Daiichi Sankyo Co Ltd ADR stock price live, this page displays OTC DSNKY stock exchange data. View the DSNKY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Daiichi Sankyo Co Ltd ADR real time stock price chart below.
What Is the Daiichi Sankyo Co Ltd ADR Stock Price Today?
The Daiichi Sankyo Co Ltd ADR stock price today is 31.35.
What Is the Stock Symbol for Daiichi Sankyo Co Ltd ADR?
The stock symbol for Daiichi Sankyo Co Ltd ADR is "DSNKY."
What Stock Exchange Does Daiichi Sankyo Co Ltd ADR Trade On?
Daiichi Sankyo Co Ltd ADR is listed and trades on the OTC Markets stock exchange.
Is Daiichi Sankyo Co Ltd ADR a Good Stock to Buy?
Determining whether Daiichi Sankyo Co Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DSNKY quote. (ISIN: US23381D1028)
What Is the Daiichi Sankyo Co Ltd ADR Stock Price Today?
The Daiichi Sankyo Co Ltd ADR stock price today is 31.35.
What Is the Stock Symbol for Daiichi Sankyo Co Ltd ADR?
The stock symbol for Daiichi Sankyo Co Ltd ADR is "DSNKY."
What Stock Exchange Does Daiichi Sankyo Co Ltd ADR Trade On?
Daiichi Sankyo Co Ltd ADR is listed and trades on the OTC Markets stock exchange.
Is Daiichi Sankyo Co Ltd ADR a Good Stock to Buy?
Determining whether Daiichi Sankyo Co Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DSNKY quote. (ISIN: US23381D1028)
31.35
-0.12(-0.38%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.08
31.45
52 wk Range
26.47
42.48
DSNKY Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.0831.45
52 wk Range
26.4742.48
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockDSNKY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
41.50
Upside
+32.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Management has been aggressively buying back shares
Daiichi Sankyo ADR Company Profile
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.
Compare DSNKY to Peers and Sector
Metrics to compare | DSNKY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDSNKYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 35.2x | 19.4x | −0.7x | |
PEG Ratio | 0.51 | 0.10 | 0.00 | |
Price/Book | 5.4x | 1.2x | 2.6x | |
Price / LTM Sales | 5.0x | 1.8x | 3.2x | |
Upside (Analyst Target) | 31.9% | 12.0% | 44.1% | |
Fair Value Upside | Unlock | 13.7% | 8.2% | Unlock |
Analysts' Recommendations
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 41.50
(+32.38% Upside)
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 130.88
Dividend Yield
-
Annualised payout
-
5-Years Growth
-
Growth Streak
FAQ
What Is the Daiichi Sankyo ADR (DSNKY) Stock Price Today?
The Daiichi Sankyo ADR stock price today is 31.35.
What Stock Exchange Does Daiichi Sankyo ADR Trade On?
Daiichi Sankyo ADR is listed and trades on the OTC Markets stock exchange.
What Is the Stock Symbol for Daiichi Sankyo ADR?
The stock symbol for Daiichi Sankyo ADR is "DSNKY."
What Is the Daiichi Sankyo ADR Market Cap?
As of today, Daiichi Sankyo ADR market cap is 59.12B.
What is Daiichi Sankyo ADR Earnings Per Share?
The Daiichi Sankyo ADR EPS is 130.88.
From a Technical Analysis Perspective, Is DSNKY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.